Groupe
Athena, Inc. (Pink sheets GATA.PK) today posted their quarterly results for the
three months ending September 30, 2013. The company reported revenues of
$18,762,589 which is an increase of 22% when compared to the corresponding
period in 2012 and is the most revenue for a single quarter reported by the
company to date. Operating income for the quarter also increased dramatically
to $3.15 million from $2.14 million for the same period in 2012. The company
notes that the very healthy 47% increase compared to the previous year is due
to a 20% increase in operating margins. Groupe Athena attributed the increase to
a revised mix of order flow that enabled more work to be done in-house as
opposed to more costly outsourcing.

Net income after
taxes for the period increased 23% to $1.61 million or $.034 per share despite
a one time impairment charge of $618,281 related to the recent property
acquisition. Excluding this charge, net income increased 70% to $2.23 million
for the period. 

The company?s order position is also healthy and management
expects total revenues of $65 million for the current fiscal year. As
mentioned in previous updates, additions to equipment continue to result in
savings and as a result, operating margins increased to 16.77% from 13.93% in
the corresponding quarter of 2012. Management remains focused on attaining
operating margins of 40% of revenues. Cash reserves remain strong and
continue to grow and long term debt remains virtually non-existent.

To review the complete
quarterly report please go to www.otcmarkets.com/stock/GATA/quote
and click on ?Financials?.

The Indian
pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to
help them get their products approved by the FDA for sales in the US. All of
these are potential clients and the Company believes it has an advantage over
competitors due to the facilities based in India, and their ability to deliver
quick feedback to clients that could result in expedited order generation. With
recent additions to equipment, the company will continue to take on additional
contracts and continue to anticipate further growth.

About
Groupe Athena, Inc.

Groupe Athena Inc. was
incorporated in June 2008 and began operations on July 1 of that year. The
company is a research and testing organization and helps various pharmaceutical
and medical products and devices companies in India
and Southeast Asia to get regulatory approvals and facilitate exports of their
products to the United
States. The Company accomplishes this by
assisting clients from concept through development, providing consultation on
regulatory requirements, filings and processes.

The company has a research and marketing
facility in India
that currently employs 18 consultants and marketing personnel and is working towards
aggressively expanding its presence in the Indian pharmaceutical industry. The
Company?s web address is www.groupeathena.com

For more information contact:

Paul Cornell

Corporate Shareholder Relations, Inc.

Cornellpaul6@gmail.com

Safe Harbor Statement

Certain statements set forth in this press
release constitute "forward-looking statements.? Forward-looking
statements include, without limitation, any statement that may predict,
forecast, indicate, or imply future results, performance or achievements, and
may contain the words "estimate", "project", "intend",
"forecast", "anticipate", "plan",
"planning", "expect", "believe", "will
likely", "should", "could", "would",
"may" or words or expressions of similar meaning. Such statements are
not guarantees of future performance and are subject to risks and uncertainties
that could cause the company's actual results and financial position to differ
materially from those included within the forward-looking statements.
Forward-looking statements involve risks and uncertainties, including those
relating to the Company's ability to grow its business. Actual results may
differ materially from the results predicted and reported results should not be
considered as an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited operating history,
the limited financial resources, domestic or global economic conditions -- activities
of competitors and the presence of new or additional competition and conditions
of equity markets.